Pain after abdominal surgery
Conditions
Interventions
Anrelifin Analgesia Observation Group:None
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in this study and sign a written, dated informed consent form. 2. Aged between 18 and 65 years, regardless of gender. 3. Undergoing elective or emergency abdominal surgery, requiring postoperative analgesia with Anrekfen injection. 4. Expected postoperative hospital stay of =72 hours, able to cooperate with the assessments and blood sample collection required for this study. 5. Conscious, with normal communication abilities, capable of accurately describing pain levels and completing the NRS scoring.
Exclusion criteria
Exclusion criteria: 1. Known allergy to Anrikefon or any of its excipients. 2. Patients with severe cardiac insufficiency (NYHA Class III-IV), severe hepatic insufficiency (Child-Pugh Class C), severe renal insufficiency (estimated glomerular filtration rate eGFR < 30 mL/min/1.73m²), or those requiring renal replacement therapy. 3. Pregnant or lactating women. 4. Concurrent use of other medications that may significantly affect the analgesic efficacy or pharmacokinetics of Anruikefen. 5. Patients with severe neurological or psychiatric disorders leading to impaired consciousness, cognitive dysfunction, or inability to reliably assess pain. 6. History of drug abuse (e.g., opioids, sedative-hypnotics) or alcohol dependence. 7. Concurrent participation in other drug clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between plasma concentration and NRS score;Renal Function Parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events; | — |
Countries
China
Contacts
Public ContactZhai Xuejia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed